TMPYP4 exerted antitumor effects in human cervical cancer cells through activation of p38 mitogen-activated protein
1Department of Gynaecology, Shanghai Jiading District Maternal and Child Care Hospital, No. 1216, Gaotai Road, Jiading District, Shanghai, 201821, China.
Background:
The aim of the present study was to investigate the potential effects of the 5,10,15,20-tetrakis (1-methylpyridinium-4-yl) porphyrin (TMPyP4) on the proliferation and apoptosis of human cervical cancer cells and the underlying mechanisms by which TMPyP4 exerted its actions.
Results:
After human cervical cancer cells were treated with different doses of TMPyP4, cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method, the apoptosis was observed by flow cytometry (FCM), and the expression of p38 mitogen-activated protein kinase (MAPK), phosphated p38 MAPK (p-p38 MAPK), capase-3, MAPKAPK2 (MK-2) and poly ADP-ribose polymerase (PARP) was measured by Western blot analysis. The analysis revealed that TMPyP4 potently suppressed cell viability and induced the apoptosis of human cervical cancer cells in a dose-dependent manner. In addition, the up-regulation of p-p38 MAPK expression levels was detected in TMPyP4-treated human cervical cancer cells. However, followed by the block of p38 MAPK signaling pathway using the inhibitor SB203580, the effects of TMPyP4 on proliferation and apoptosis of human cervical cancer cells were significantly changed.
Conclusions:
It was indicated that TMPyP4-inhibited proliferation and -induced apoptosis in human cervical cancer cells was accompanied by activating the p38 MAPK signaling pathway. Taken together, our study demonstrates that TMPyP4 may represent a potential therapeutic method for the treatment of cervical carcinoma.
Insights
The compound 5,10,15,20-tetrakis(1-methylpyridinium-4-yl) porphyrin (TMPyP4) inhibits human cervical cancer cell proliferation and induces apoptosis. This occurs through the activation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cervical cancer remains a significant global health challenge.
- Investigating novel therapeutic agents is crucial for improving treatment outcomes.
- 5,10,15,20-tetrakis(1-methylpyridinium-4-yl) porphyrin (TMPyP4) is a potential candidate for cancer therapy.
Purpose of the Study:
- To evaluate the effects of TMPyP4 on human cervical cancer cell proliferation and apoptosis.
- To elucidate the underlying molecular mechanisms, specifically focusing on the p38 MAPK signaling pathway.
Main Methods:
- Human cervical cancer cells were treated with varying doses of TMPyP4.
- Cell viability was assessed using the MTT assay.
- Apoptosis was analyzed via flow cytometry (FCM).
- Protein expression levels of p38 MAPK, p-p38 MAPK, caspase-3, MK-2, and PARP were measured by Western blot.
- The p38 MAPK signaling pathway was inhibited using SB203580 to assess its role.
Main Results:
- TMPyP4 significantly suppressed cell viability and induced apoptosis in a dose-dependent manner.
- TMPyP4 treatment led to the up-regulation of phosphorylated p38 MAPK (p-p38 MAPK) expression.
- Inhibition of the p38 MAPK pathway altered the effects of TMPyP4 on proliferation and apoptosis.
Conclusions:
- TMPyP4-mediated inhibition of proliferation and induction of apoptosis in cervical cancer cells are linked to the activation of the p38 MAPK signaling pathway.
- TMPyP4 shows promise as a potential therapeutic agent for cervical carcinoma.
- Further research into TMPyP4's mechanism and efficacy is warranted.
Related Concept Videos
02:23Abnormal Proliferation
01:31The Intrinsic Apoptotic Pathway
01:15Drugs that Stabilize Microtubules
02:38Mitogens and the Cell Cycle